<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04356937</url>
  </required_header>
  <id_info>
    <org_study_id>2020P001159</org_study_id>
    <nct_id>NCT04356937</nct_id>
  </id_info>
  <brief_title>Efficacy of Tocilizumab on Patients With COVID-19</brief_title>
  <official_title>Tocilizumab to Prevent the Progression of Hypoxemic Respiratory Failure in Hospitalized Non-Critically Ill Patients With COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double blind, multi-center study to evaluate the effects of tocilizumab&#xD;
      compared to placebo on patient outcomes in participants with confirmed SARS-CoV-2 infection&#xD;
      and evidence of systemic inflammation.&#xD;
&#xD;
      The aim of this study is to test the effect of Tocilizumab on multi-organ dysfunction in a&#xD;
      phase 3 randomized controlled trial among hospitalized patients with COVID-19 infection.&#xD;
&#xD;
      Specifically, as compared to placebo, we will test whether tocilizumab is associated with a&#xD;
      reduction in multi-organ dysfunction among hospitalized COVID-19 adult patients with elevated&#xD;
      inflammatory measures. Multi-organ dysfunction will be measured as the incidence of the&#xD;
      following composite endpoint (mechanical ventilation, renal replacement therapy, mechanical&#xD;
      support, need for inotropes or vasopressors, liver dysfunction (increased bilirubin), and&#xD;
      all-cause mortality). We will also assess multiple pre-specified secondary (exploratory)&#xD;
      endpoints and safety endpoints.&#xD;
&#xD;
      We hypothesize that, as compared to placebo, tocilizumab will reduce transfer to the ICU,&#xD;
      need for mechanical ventilation, increase rates of hospital discharge in patients diagnosed&#xD;
      with severe COVID-19 infection and evidence of exaggerated inflammatory response.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      As of April 3, 2020, COVID-19 has been confirmed in over 1 million people worldwide, with an&#xD;
      estimated symptomatic case fatality ratio of around 1.4%. Currently without an effective&#xD;
      treatment for SARS-CoV-2 there is an urgent need for effective treatment to curtail the rate&#xD;
      of respiratory failure, the leading cause of mortality in COVID-19 disease. Moreover, with&#xD;
      increasing numbers of patients requiring intensive unit level care and mechanical&#xD;
      ventilation, nations are already having to triage patients for ventilatory support due to&#xD;
      limited resources and healthcare systems around the world being stretched to the point of&#xD;
      collapse, highlighting the importance of identifying interventions that could prevent the&#xD;
      development of respiratory failure for these patients.&#xD;
&#xD;
      The disease course of COVID-19 includes an incubation period, an acute viral phase that most&#xD;
      commonly presents with flu-like symptoms that in some individuals progresses to a severe&#xD;
      hyperinflammatory phase marked by acute respiratory distress syndrome (ARDS) and hypoxemic&#xD;
      respiratory failure.Though there is spectrum of clinical course, many progress to the&#xD;
      hyperinflammatory phase around day seven of symptoms, often requiring intensive care unit&#xD;
      (ICU) level care and mechanical ventilation. Accumulating evidence suggests that the&#xD;
      pathophysiology underlying this profound decline is a severe inflammatory response as&#xD;
      demonstrated by multi organ system dysfunction akin to cytokine release syndrome&#xD;
      (CRS)/macrophage activation syndrome (MAS).CRS/MAS is a systemic hyperinflammatory syndrome&#xD;
      on a spectrum with secondary hemophagocytic lymphohistiocytosis (sHLH), typically&#xD;
      characterized by multiorgan failure that is often triggered by viral infections in the&#xD;
      setting of excessive immune activation, typically with marked hyperferritinemia.Postmortem&#xD;
      assessment of patients with COVID-19 have demonstrated pathologic findings consistent with&#xD;
      MAS such as mono/lymphocytic infiltrates within the lung parenchyma with associated edema and&#xD;
      alveolar congestion, splenic necrosis with macrophage proliferation and hemophagocytosis, as&#xD;
      well as a lymphocyte/histiocyte predominate infiltrate of portal vasculature accompanying&#xD;
      liver necrosis and sinusoidal congestion.Cytokine profiling of patients with MAS/sHLH&#xD;
      overlaps with that seen in patients with severe COVID-19 and includes elevated levels of&#xD;
      IL-1, IL-2, IL-7, IL-6, G-CSF, MCP- 1, and TNF-Î± as well as elevated D-dimer, C-reactive&#xD;
      protein, LDH and troponins.Moreover, preliminary data from a non-randomized series of&#xD;
      COVID-19 patients with &quot;severe or critical COVID-19&quot; from China who were treated with&#xD;
      tocilizumab (in addition to standard therapies) showed they had dramatic improvement in&#xD;
      fever, arterial oxygen saturation and inflammatory markers within the first 24-hours&#xD;
      following administration.&#xD;
&#xD;
      Taken together, these data strongly suggest an immunologic link between COVID-19 and immune&#xD;
      dysregulation resulting in MAS. Clinical trials are already underway studying the role of&#xD;
      immunomodulatory therapy including modulation of IL-1 and IL-6 and downstream pathways in the&#xD;
      setting of CAR-T induced MAS (NCT04150913, NCT04071366) and agents such anakinra and&#xD;
      tocilizumab have been used in this context with promising results and good safety profiles.&#xD;
      There is an urgent and dire need to study the therapeutic role for immunomodulatory therapy&#xD;
      in COVID-19 disease to both halt disease progression in patients at an individual level and&#xD;
      prevent the inevitable saturation of healthcare resources at a systems level, to which end&#xD;
      there are numerous ongoing international trials to expand these efforts into the setting of&#xD;
      COVID-19 infection (ChiCTR2000029765, NCT04324021, TOCOVID-19). Based on the MGH experience&#xD;
      thus far with COVID-19, including over 200 patients to date, the need for mechanical&#xD;
      ventilation has been approximately 30%. With the upcoming surge anticipated between April&#xD;
      17th and 21st we expect the need for hundreds of additional ICU beds. Investigators propose a&#xD;
      trial of IL-6 receptor blockade with tocilizumab given early in disease course to try to&#xD;
      prevent progression of COVID-19.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 20, 2020</start_date>
  <completion_date type="Actual">August 27, 2020</completion_date>
  <primary_completion_date type="Actual">July 13, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Prospective, multi-center, randomized,double blind, placebo-controlled trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Subjects who meet all inclusion criteria and none of the exclusion criteria will be randomized 2:1 to tocilizumab or placebo.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Mechanical Ventilation or Death</measure>
    <time_frame>28 days</time_frame>
    <description>Time from administration of the investigational agent (or placebo) to requiring mechanical ventilation and intubation, or death for subjects who die prior to intubation. The percentages of patients who have been intubated or died as of day 14 and day 28 are estimated from the Kaplan-Meier curve.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Worsening on Ordinal Scale</measure>
    <time_frame>28 days</time_frame>
    <description>Time from administration of the investigational medication (or placebo) to at least one point worsening on the clinical improvement scale for subjects requiring supplemental oxygen (score &gt;= 3) at baseline, or at least two point worsening otherwise (score = 2 at baseline). The percentages of patients who have worsened as of day 14 and day 28 are estimated from the Kaplan-Meier curve.&#xD;
Ordinal Scale&#xD;
Discharged&#xD;
Non-ICU hospital ward not requiring supplemental oxygen&#xD;
Non-ICU hospital ward requiring supplemental oxygen&#xD;
ICU or non-ICU hospital ward, requiring non-invasive ventilation or high-flow oxygen&#xD;
ICU, requiring intubation and mechanical ventilation&#xD;
ICU, requiring ECMO or mechanical ventilation and additional organ support&#xD;
Death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Discontinuation of Supplemental Oxygen Among Patients Receiving it at Baseline</measure>
    <time_frame>28 days</time_frame>
    <description>Time from administration of the investigational agent (or placebo) to absence of the need for supplemental oxygen among those who require at least supplemental oxygen at baseline. The percentages of patients who have discontinued supplemental oxygen as of day 14 and day 28 are estimated from the Kaplan-Meier curve.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Duration of Supplemental Oxygen</measure>
    <time_frame>28 days</time_frame>
    <description>Time from initiation of supplemental oxygen to end of supplemental oxygen use during 28-day study follow-up period. We includes all subjects in the analysis by assigning all subjects who did not receive supplemental oxygen a value of 0. Subjects who died prior to discontinuation of supplemental oxygen were given a value of the number of days from when supplemental oxygen began until the end of the follow-up period.</description>
  </other_outcome>
  <other_outcome>
    <measure>Duration of Mechanical Ventilation</measure>
    <time_frame>28 days</time_frame>
    <description>Time from initiation of mechanical ventilation to end of mechanical ventilation during 28-day study follow-up period, among patients who received mechanical ventilation. Event times of patients who died without discontinuation of mechanical ventilation were censored at 28 days. Median and inter-quartile range (IQR) were estimated using Kaplan-Meier curves. The upper limit for the IQR was not reached for both arms and entered as 28 in the outcome measure data table.</description>
  </other_outcome>
  <other_outcome>
    <measure>Mortality</measure>
    <time_frame>28 days</time_frame>
    <description>Time from administration of the investigational agent (or placebo) to death. The percentage of patients who have died as of day 14 and day 28 are estimated from the Kaplan-Meier curve.</description>
  </other_outcome>
  <other_outcome>
    <measure>ICU Admission or Death Among Those Not in the ICU at the Time of Administration of Investigational Agent (or Placebo)</measure>
    <time_frame>28 days</time_frame>
    <description>The percentage of subjects requiring ICU admission between baseline and 28 days is calculated by dividing the number of subjects requiring ICU admission over their hospitalization by the number of evaluable subjects (i.e., the number of subjects not in the ICU at the time of investigational treatment administration).</description>
  </other_outcome>
  <other_outcome>
    <measure>Hospital Discharge</measure>
    <time_frame>28 days</time_frame>
    <description>Time from administration of the investigational medication (or placebo) to initial hospital discharge. Event times for patient who die are censored at day 29 to indicate that they never left the hospital during the follow-up period. The percentages of patients who were discharged as of day 14 and day 28 are estimated from the Kaplan-Meier curve.</description>
  </other_outcome>
  <other_outcome>
    <measure>Clinical Improvement on Ordinal Scale</measure>
    <time_frame>28 days</time_frame>
    <description>Time to first improvement from administration of the investigational agent (or placebo) of at least 2 points (or the maximum amount) on the ordinal scale. Event times for patients who died prior to reaching this endpoint are censored at 29 days.&#xD;
Ordinal Scale&#xD;
Discharged&#xD;
Non-ICU hospital ward not requiring supplemental oxygen&#xD;
Non-ICU hospital ward requiring supplemental oxygen&#xD;
ICU or non-ICU hospital ward, requiring non-invasive ventilation or high-flow oxygen&#xD;
ICU, requiring intubation and mechanical ventilation&#xD;
ICU, requiring ECMO or mechanical ventilation and additional organ support&#xD;
Death</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">243</enrollment>
  <condition>SARS-CoV 2</condition>
  <arm_group>
    <arm_group_label>Tocilizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Review effect of Tocilizumab on multi-organ dysfunction in a phase 3 randomized controlled trial among hospitalized patients with COVID-19 infection.&#xD;
Participants will receive an intravenous (IV) injection of 8 mg/kg (not to exceed 800 mg) tocilizumab.Specifically, as compared to placebo, we will test whether tocilizumab is associated with a reduction in multi-organ dysfunction among hospitalized COVID-19 adult patients with elevated inflammatory measures.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of care plus placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive an placebo intravenous (IV) injection of 8 mg/kg (not to exceed 800 mg).Specifically, as compared to placebo, we will test whether tocilizumab is associated with a reduction in multi-organ dysfunction among hospitalized COVID-19 adult patients with elevated inflammatory measures.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tocilizumab</intervention_name>
    <description>Patients will receive the standard treatment for COVID-19 per MGH guidance and also be randomized (2:1) to one of the following arms:&#xD;
Tocilizumab 8mg x 1 (n=185)&#xD;
Standard of care/Placebo (n=93)</description>
    <arm_group_label>Tocilizumab</arm_group_label>
    <other_name>Actemra</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <description>Patients will receive the standard treatment for COVID-19 per MGH guidance and also be randomized (2:1) to one of the following arms:&#xD;
Tocilizumab 8mg x 1 (n=185)&#xD;
Standard of care/Placebo (n=93)</description>
    <arm_group_label>Standard of care plus placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
        Subjects who meet all of the following criteria will be eligible to participate in the&#xD;
        study:&#xD;
&#xD;
          1. Must have provided informed consent in a manner approved by the Investigator's&#xD;
             Institutional Review Board (IRB) or Independent Ethics Committee (IEC) prior to any&#xD;
             assessments. If a patient is unable to provide informed consent due to their medical&#xD;
             condition, the patient's legally authorized representative may consent on behalf of&#xD;
             the study patient, as permitted by local law and institutional Standard Operating&#xD;
             Procedures;&#xD;
&#xD;
          2. Age Range: 19-85 years old&#xD;
&#xD;
          3. Male or female gender&#xD;
&#xD;
          4. Confirmed SARS-CoV-2 infection by nasopharyngeal swab PCR or serum assay for IgM&#xD;
             antibody&#xD;
&#xD;
          5. Requiring hospital but not mechanical ventilation&#xD;
&#xD;
          6. Oxygen supplementation not greater than 10L delivered by any device&#xD;
&#xD;
          7. WITH evidence of severe COVID-19 (at least 2 of the following):&#xD;
&#xD;
               1. Fever &gt; 38C within 72 hours&#xD;
&#xD;
               2. Pulmonary infiltrate on CXR&#xD;
&#xD;
               3. Need for supplemental O2 to maintain saturation &gt; 92%&#xD;
&#xD;
          8. AND at least 1 of the following:&#xD;
&#xD;
               1. Ferritin &gt; 500 ng/ml&#xD;
&#xD;
               2. CRP &gt; 50 mg/L&#xD;
&#xD;
               3. LDH &gt;250 U/L&#xD;
&#xD;
               4. D-dimer &gt; 1000 ng/mL&#xD;
&#xD;
          9. Women of childbearing potential (ie, not post-menopausal or surgically sterilized)&#xD;
             must have a negative highly sensitive urine or serum pregnancy test before&#xD;
             randomization. Participating women of childbearing potential must be willing to&#xD;
             consistently use effective methods of contraception (ie, condom, combined oral&#xD;
             contraceptive, implant, injectable, indwelling intrauterine device, or a vasectomized&#xD;
             partner) from screening until at least 90 days after administration of the last dose&#xD;
             of study drug;&#xD;
&#xD;
         10. The subject must be willing and able to provide informed consent and abide all study&#xD;
             requirements and restrictions.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
        Subjects who meet any of the following criteria will be excluded from participation in the&#xD;
        study:&#xD;
&#xD;
          1. Unable to provide verbal informed consent or have verbal agreement to participate&#xD;
             through attestation and signature of a Witness required, as outlined in the Partners&#xD;
             IRB's Table for Consenting in COVID Research that is More than Minimal Risk.&#xD;
&#xD;
          2. Subjects between the ages of 79 and 86 will be excluded if they have NYHA Class III/IV&#xD;
             heart failure, insulin-dependent diabetes mellitus, angina, or treatment of a&#xD;
             malignancy (excluding non-melanoma skin cancer) within six months&#xD;
&#xD;
          3. Uncontrolled bacterial, fungal, or non-COVID viral infection&#xD;
&#xD;
          4. Active TB&#xD;
&#xD;
          5. Any prior investigational immunosuppressive therapy within 28-days or 3 half-lives of&#xD;
             the agent (for instance with biologic or JAK inhibitor)&#xD;
&#xD;
          6. Any concurrent immunosuppressive medication that the PI believes would put the patient&#xD;
             at higher risk&#xD;
&#xD;
          7. Receipt of intravenous tocilizumab for the treatment of a non-COVID condition within&#xD;
             three weeks of the first COVID symptom&#xD;
&#xD;
          8. History of hypersensitivity to tocilizumab&#xD;
&#xD;
          9. Any concurrent immunosuppressive medication that the PI believes would put the patient&#xD;
             at higher risk&#xD;
&#xD;
         10. Treatment with other biologic or small-molecule immunosuppressive therapy such as&#xD;
             IL1R-antagonism, JAK inhibition, or other agents&#xD;
&#xD;
         11. Treatment with convalescent plasma&#xD;
&#xD;
         12. History of diverticulitis or bowel perforation&#xD;
&#xD;
         13. ANC &lt;500, Platelets &lt;50,000*&#xD;
&#xD;
         14. AST/ALT &gt; 5X ULN&#xD;
&#xD;
         15. Women who are pregnant or planning to get pregnant in the next 90 days;&#xD;
&#xD;
         16. Any condition that could interfere with, or for Known allergy to the study drug or any&#xD;
             of its ingredients or known allergy to any other anti IL 6 agents;&#xD;
&#xD;
         17. Any condition that could interfere with or for which the treatment might interfere&#xD;
             with, the conduct of the study or interpretation of the study results, or that would,&#xD;
             in the opinion of the Investigator, increase the risk of the subject by participating&#xD;
             in the study.&#xD;
&#xD;
        We note that anti-viral therapies may be administered to subjects if given in the context&#xD;
        of a clinical trial. Nitric oxide treatment is also permitted at the discretion of the care&#xD;
        team, ideally in the context of a clinical trial. Co-treatment chloroquine,&#xD;
        hydroxychloroquine, and/or azithromycin is permitted for subjects in this protocol.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John H Stone, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Newton-Wellesley Hospital</name>
      <address>
        <city>Newton</city>
        <state>Massachusetts</state>
        <zip>02462</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>April 19, 2020</study_first_submitted>
  <study_first_submitted_qc>April 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 22, 2020</study_first_posted>
  <results_first_submitted>June 23, 2021</results_first_submitted>
  <results_first_submitted_qc>July 23, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">July 27, 2021</results_first_posted>
  <last_update_submitted>July 23, 2021</last_update_submitted>
  <last_update_submitted_qc>July 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Stone, John H, M.D., M.P.H</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Request for IPD can be submitted to PI for review</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>August 18, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/37/NCT04356937/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 18, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/37/NCT04356937/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Tocilizumab</title>
          <description>Standard care plus a single dose of tocilizumab (8 mg/kg administered intravenously, not to exceed 800 mg)</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Standard care plus placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Randomization (Safety Population)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="161"/>
                <participants group_id="P2" count="82"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="161"/>
                <participants group_id="P2" count="82"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Treatment (mITT Population)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="161"/>
                <participants group_id="P2" count="82"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="161"/>
                <participants group_id="P2" count="81"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Intubated before receiving study treatment</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All randomized patients</population>
      <group_list>
        <group group_id="B1">
          <title>Tocilizumab</title>
          <description>Review effect of Tocilizumab on multi-organ dysfunction in a phase 3 randomized controlled trial among hospitalized patients with COVID-19 infection.&#xD;
Participants will receive an intravenous (IV) injection of 8 mg/kg (not to exceed 800 mg) tocilizumab. Specifically, as compared to placebo, we will test whether tocilizumab is associated with a reduction in multi-organ dysfunction among hospitalized COVID-19 adult patients with elevated inflammatory measures.&#xD;
Tocilizumab: Patients will receive the standard treatment for COVID-19 per MGH guidance and also be randomized (2:1) to one of the following arms:&#xD;
Tocilizumab 8mg x 1&#xD;
Standard of care/Placebo</description>
        </group>
        <group group_id="B2">
          <title>Standard of Care Plus Placebo</title>
          <description>Participants will receive an placebo intravenous (IV) injection of 8 mg/kg (not to exceed 800 mg).Specifically, as compared to placebo, we will test whether tocilizumab is associated with a reduction in multi-organ dysfunction among hospitalized COVID-19 adult patients with elevated inflammatory measures.&#xD;
Placebos: Patients will receive the standard treatment for COVID-19 per MGH guidance and also be randomized (2:1) to one of the following arms:&#xD;
Tocilizumab 8mg x 1&#xD;
Standard of care/Placebo</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="161"/>
            <count group_id="B2" value="82"/>
            <count group_id="B3" value="243"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.6" lower_limit="46.4" upper_limit="69.7"/>
                    <measurement group_id="B2" value="56.5" lower_limit="44.7" upper_limit="67.8"/>
                    <measurement group_id="B3" value="59.8" lower_limit="45.3" upper_limit="69.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="65"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="102"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="96"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="141"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="70"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="109"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="84"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="119"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Race or ethnic group</title>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="71"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="104"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="50"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="161"/>
                    <measurement group_id="B2" value="82"/>
                    <measurement group_id="B3" value="243"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <units>kg/m^2</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29.9" lower_limit="26.0" upper_limit="34.2"/>
                    <measurement group_id="B2" value="30.2" lower_limit="25.7" upper_limit="33.8"/>
                    <measurement group_id="B3" value="30.1" lower_limit="25.9" upper_limit="34.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI â¥ 30 kg/m^2</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="80"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="122"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Days from symptom onset to randomization</title>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9.0" lower_limit="6.0" upper_limit="13.0"/>
                    <measurement group_id="B2" value="10.0" lower_limit="7.0" upper_limit="13.0"/>
                    <measurement group_id="B3" value="9.0" lower_limit="6.0" upper_limit="13.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hypertension</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="80"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="118"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Heart failure</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>History of myocardial infarction</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Chronic obstructive pulmonary disorder</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Asthma</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Smoking status</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Current smoker</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Former smoker</title>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="72"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Lifelong nonsmoker</title>
                  <measurement_list>
                    <measurement group_id="B1" value="99"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="147"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diabetes</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>History of cancer</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mechanical Ventilation or Death</title>
        <description>Time from administration of the investigational agent (or placebo) to requiring mechanical ventilation and intubation, or death for subjects who die prior to intubation. The percentages of patients who have been intubated or died as of day 14 and day 28 are estimated from the Kaplan-Meier curve.</description>
        <time_frame>28 days</time_frame>
        <population>Modified intention-to-treat (mITT) population, which includes 242 patients (161 in the tocilizumab group and 81 in the placebo group) who underwent randomization and received either tocilizumab or placebo before intubation or death</population>
        <group_list>
          <group group_id="O1">
            <title>Tocilizumab</title>
            <description>Standard care plus a single dose of tocilizumab (8 mg/kg administered intravenously, not to exceed 800 mg)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Standard care plus placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Mechanical Ventilation or Death</title>
          <description>Time from administration of the investigational agent (or placebo) to requiring mechanical ventilation and intubation, or death for subjects who die prior to intubation. The percentages of patients who have been intubated or died as of day 14 and day 28 are estimated from the Kaplan-Meier curve.</description>
          <population>Modified intention-to-treat (mITT) population, which includes 242 patients (161 in the tocilizumab group and 81 in the placebo group) who underwent randomization and received either tocilizumab or placebo before intubation or death</population>
          <units>percentage of patients with event</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="161"/>
                <count group_id="O2" value="81"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>14 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.9" lower_limit="6.2" upper_limit="15.7"/>
                    <measurement group_id="O2" value="10.0" lower_limit="5.1" upper_limit="18.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>28 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.6" lower_limit="6.7" upper_limit="16.6"/>
                    <measurement group_id="O2" value="12.5" lower_limit="6.9" upper_limit="22.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.64</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.83</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.38</ci_lower_limit>
            <ci_upper_limit>1.81</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Worsening on Ordinal Scale</title>
        <description>Time from administration of the investigational medication (or placebo) to at least one point worsening on the clinical improvement scale for subjects requiring supplemental oxygen (score &gt;= 3) at baseline, or at least two point worsening otherwise (score = 2 at baseline). The percentages of patients who have worsened as of day 14 and day 28 are estimated from the Kaplan-Meier curve.&#xD;
Ordinal Scale&#xD;
Discharged&#xD;
Non-ICU hospital ward not requiring supplemental oxygen&#xD;
Non-ICU hospital ward requiring supplemental oxygen&#xD;
ICU or non-ICU hospital ward, requiring non-invasive ventilation or high-flow oxygen&#xD;
ICU, requiring intubation and mechanical ventilation&#xD;
ICU, requiring ECMO or mechanical ventilation and additional organ support&#xD;
Death</description>
        <time_frame>28 days</time_frame>
        <population>Modified intention-to-treat (mITT) population, which includes 242 patients (161 in the tocilizumab group and 81 in the placebo group) who underwent randomization and received either tocilizumab or placebo before intubation or death</population>
        <group_list>
          <group group_id="O1">
            <title>Tocilizumab</title>
            <description>Standard care plus a single dose of tocilizumab (8 mg/kg administered intravenously, not to exceed 800 mg)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Standard care plus placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Worsening on Ordinal Scale</title>
          <description>Time from administration of the investigational medication (or placebo) to at least one point worsening on the clinical improvement scale for subjects requiring supplemental oxygen (score &gt;= 3) at baseline, or at least two point worsening otherwise (score = 2 at baseline). The percentages of patients who have worsened as of day 14 and day 28 are estimated from the Kaplan-Meier curve.&#xD;
Ordinal Scale&#xD;
Discharged&#xD;
Non-ICU hospital ward not requiring supplemental oxygen&#xD;
Non-ICU hospital ward requiring supplemental oxygen&#xD;
ICU or non-ICU hospital ward, requiring non-invasive ventilation or high-flow oxygen&#xD;
ICU, requiring intubation and mechanical ventilation&#xD;
ICU, requiring ECMO or mechanical ventilation and additional organ support&#xD;
Death</description>
          <population>Modified intention-to-treat (mITT) population, which includes 242 patients (161 in the tocilizumab group and 81 in the placebo group) who underwent randomization and received either tocilizumab or placebo before intubation or death</population>
          <units>percentage of patients with event</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="161"/>
                <count group_id="O2" value="81"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.0" lower_limit="12.9" upper_limit="24.9"/>
                    <measurement group_id="O2" value="14.9" lower_limit="8.7" upper_limit="24.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.3" lower_limit="14.0" upper_limit="26.2"/>
                    <measurement group_id="O2" value="17.4" lower_limit="10.7" upper_limit="27.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.73</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.11</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.59</ci_lower_limit>
            <ci_upper_limit>2.10</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Discontinuation of Supplemental Oxygen Among Patients Receiving it at Baseline</title>
        <description>Time from administration of the investigational agent (or placebo) to absence of the need for supplemental oxygen among those who require at least supplemental oxygen at baseline. The percentages of patients who have discontinued supplemental oxygen as of day 14 and day 28 are estimated from the Kaplan-Meier curve.</description>
        <time_frame>28 days</time_frame>
        <population>A subset of 204 patients from the modified intention-to-treat (mITT) population who required at least supplemental oxygen at baseline. 138 patients in the tocilizumab group and 66 patients in the placebo group required at least supplemental oxygen at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>Tocilizumab</title>
            <description>Standard care plus a single dose of tocilizumab (8 mg/kg administered intravenously, not to exceed 800 mg)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Standard care plus placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Discontinuation of Supplemental Oxygen Among Patients Receiving it at Baseline</title>
          <description>Time from administration of the investigational agent (or placebo) to absence of the need for supplemental oxygen among those who require at least supplemental oxygen at baseline. The percentages of patients who have discontinued supplemental oxygen as of day 14 and day 28 are estimated from the Kaplan-Meier curve.</description>
          <population>A subset of 204 patients from the modified intention-to-treat (mITT) population who required at least supplemental oxygen at baseline. 138 patients in the tocilizumab group and 66 patients in the placebo group required at least supplemental oxygen at baseline.</population>
          <units>percentage of patients with event</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="138"/>
                <count group_id="O2" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.4" lower_limit="67.9" upper_limit="82.2"/>
                    <measurement group_id="O2" value="78.8" lower_limit="68.3" upper_limit="87.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.6" lower_limit="75.9" upper_limit="88.4"/>
                    <measurement group_id="O2" value="84.9" lower_limit="75.2" upper_limit="92.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.69</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.94</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.67</ci_lower_limit>
            <ci_upper_limit>1.30</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Duration of Supplemental Oxygen</title>
        <description>Time from initiation of supplemental oxygen to end of supplemental oxygen use during 28-day study follow-up period. We includes all subjects in the analysis by assigning all subjects who did not receive supplemental oxygen a value of 0. Subjects who died prior to discontinuation of supplemental oxygen were given a value of the number of days from when supplemental oxygen began until the end of the follow-up period.</description>
        <time_frame>28 days</time_frame>
        <population>Modified intention-to-treat (mITT) population, which includes 242 patients (161 in the tocilizumab group and 81 in the placebo group) who underwent randomization and received either tocilizumab or placebo before intubation or death</population>
        <group_list>
          <group group_id="O1">
            <title>Tocilizumab</title>
            <description>Standard care plus a single dose of tocilizumab (8 mg/kg administered intravenously, not to exceed 800 mg)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Standard care plus placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Supplemental Oxygen</title>
          <description>Time from initiation of supplemental oxygen to end of supplemental oxygen use during 28-day study follow-up period. We includes all subjects in the analysis by assigning all subjects who did not receive supplemental oxygen a value of 0. Subjects who died prior to discontinuation of supplemental oxygen were given a value of the number of days from when supplemental oxygen began until the end of the follow-up period.</description>
          <population>Modified intention-to-treat (mITT) population, which includes 242 patients (161 in the tocilizumab group and 81 in the placebo group) who underwent randomization and received either tocilizumab or placebo before intubation or death</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="161"/>
                <count group_id="O2" value="81"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0" lower_limit="1.8" upper_limit="11.6"/>
                    <measurement group_id="O2" value="3.9" lower_limit="1.1" upper_limit="9.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Duration of Mechanical Ventilation</title>
        <description>Time from initiation of mechanical ventilation to end of mechanical ventilation during 28-day study follow-up period, among patients who received mechanical ventilation. Event times of patients who died without discontinuation of mechanical ventilation were censored at 28 days. Median and inter-quartile range (IQR) were estimated using Kaplan-Meier curves. The upper limit for the IQR was not reached for both arms and entered as 28 in the outcome measure data table.</description>
        <time_frame>28 days</time_frame>
        <population>A subset of 19 patients from the modified intention-to-treat (mITT) population who received mechanical ventilation during the study follow-up period. 11 patients in the tocilizumab group and 8 patients in the placebo group received mechanical ventilation.</population>
        <group_list>
          <group group_id="O1">
            <title>Tocilizumab</title>
            <description>Standard care plus a single dose of tocilizumab (8 mg/kg administered intravenously, not to exceed 800 mg)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Standard care plus placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Mechanical Ventilation</title>
          <description>Time from initiation of mechanical ventilation to end of mechanical ventilation during 28-day study follow-up period, among patients who received mechanical ventilation. Event times of patients who died without discontinuation of mechanical ventilation were censored at 28 days. Median and inter-quartile range (IQR) were estimated using Kaplan-Meier curves. The upper limit for the IQR was not reached for both arms and entered as 28 in the outcome measure data table.</description>
          <population>A subset of 19 patients from the modified intention-to-treat (mITT) population who received mechanical ventilation during the study follow-up period. 11 patients in the tocilizumab group and 8 patients in the placebo group received mechanical ventilation.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.0" lower_limit="12.6" upper_limit="NA">The upper limit for the IQR was not reached in the tocilizumab group.</measurement>
                    <measurement group_id="O2" value="27.9" lower_limit="16.3" upper_limit="NA">The upper limit for the IQR was not reached in the placebo group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Mortality</title>
        <description>Time from administration of the investigational agent (or placebo) to death. The percentage of patients who have died as of day 14 and day 28 are estimated from the Kaplan-Meier curve.</description>
        <time_frame>28 days</time_frame>
        <population>Modified intention-to-treat (mITT) population, which includes 242 patients (161 in the tocilizumab group and 81 in the placebo group) who underwent randomization and received either tocilizumab or placebo before intubation or death</population>
        <group_list>
          <group group_id="O1">
            <title>Tocilizumab</title>
            <description>Standard care plus a single dose of tocilizumab (8 mg/kg administered intravenously, not to exceed 800 mg)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Standard care plus placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Mortality</title>
          <description>Time from administration of the investigational agent (or placebo) to death. The percentage of patients who have died as of day 14 and day 28 are estimated from the Kaplan-Meier curve.</description>
          <population>Modified intention-to-treat (mITT) population, which includes 242 patients (161 in the tocilizumab group and 81 in the placebo group) who underwent randomization and received either tocilizumab or placebo before intubation or death</population>
          <units>percentage of patients with event</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="161"/>
                <count group_id="O2" value="81"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.4" lower_limit="2.1" upper_limit="8.9"/>
                    <measurement group_id="O2" value="1.3" lower_limit="0.2" upper_limit="8.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.6" lower_limit="3.0" upper_limit="10.5"/>
                    <measurement group_id="O2" value="3.8" lower_limit="1.2" upper_limit="11.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>ICU Admission or Death Among Those Not in the ICU at the Time of Administration of Investigational Agent (or Placebo)</title>
        <description>The percentage of subjects requiring ICU admission between baseline and 28 days is calculated by dividing the number of subjects requiring ICU admission over their hospitalization by the number of evaluable subjects (i.e., the number of subjects not in the ICU at the time of investigational treatment administration).</description>
        <time_frame>28 days</time_frame>
        <population>A subset of 233 patients from the modified intention-to-treat (mITT) population who were not in the ICU at baseline. 157 patients in the tocilizumab group and 76 patients in the placebo group were not in the ICU at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>Tocilizumab</title>
            <description>Standard care plus a single dose of tocilizumab (8 mg/kg administered intravenously, not to exceed 800 mg)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Standard care plus placebo</description>
          </group>
        </group_list>
        <measure>
          <title>ICU Admission or Death Among Those Not in the ICU at the Time of Administration of Investigational Agent (or Placebo)</title>
          <description>The percentage of subjects requiring ICU admission between baseline and 28 days is calculated by dividing the number of subjects requiring ICU admission over their hospitalization by the number of evaluable subjects (i.e., the number of subjects not in the ICU at the time of investigational treatment administration).</description>
          <population>A subset of 233 patients from the modified intention-to-treat (mITT) population who were not in the ICU at baseline. 157 patients in the tocilizumab group and 76 patients in the placebo group were not in the ICU at baseline.</population>
          <units>percentage of patients with event</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="157"/>
                <count group_id="O2" value="76"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.9"/>
                    <measurement group_id="O2" value="15.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Hospital Discharge</title>
        <description>Time from administration of the investigational medication (or placebo) to initial hospital discharge. Event times for patient who die are censored at day 29 to indicate that they never left the hospital during the follow-up period. The percentages of patients who were discharged as of day 14 and day 28 are estimated from the Kaplan-Meier curve.</description>
        <time_frame>28 days</time_frame>
        <population>Modified intention-to-treat (mITT) population, which includes 242 patients (161 in the tocilizumab group and 81 in the placebo group) who underwent randomization and received either tocilizumab or placebo before intubation or death</population>
        <group_list>
          <group group_id="O1">
            <title>Tocilizumab</title>
            <description>Standard care plus a single dose of tocilizumab (8 mg/kg administered intravenously, not to exceed 800 mg)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Standard care plus placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Hospital Discharge</title>
          <description>Time from administration of the investigational medication (or placebo) to initial hospital discharge. Event times for patient who die are censored at day 29 to indicate that they never left the hospital during the follow-up period. The percentages of patients who were discharged as of day 14 and day 28 are estimated from the Kaplan-Meier curve.</description>
          <population>Modified intention-to-treat (mITT) population, which includes 242 patients (161 in the tocilizumab group and 81 in the placebo group) who underwent randomization and received either tocilizumab or placebo before intubation or death</population>
          <units>percentage of patients with event</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="161"/>
                <count group_id="O2" value="81"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.3" lower_limit="80.6" upper_limit="91.1"/>
                    <measurement group_id="O2" value="81.5" lower_limit="72.4" upper_limit="89.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.3" lower_limit="86.3" upper_limit="95.0"/>
                    <measurement group_id="O2" value="88.9" lower_limit="81.0" upper_limit="94.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Clinical Improvement on Ordinal Scale</title>
        <description>Time to first improvement from administration of the investigational agent (or placebo) of at least 2 points (or the maximum amount) on the ordinal scale. Event times for patients who died prior to reaching this endpoint are censored at 29 days.&#xD;
Ordinal Scale&#xD;
Discharged&#xD;
Non-ICU hospital ward not requiring supplemental oxygen&#xD;
Non-ICU hospital ward requiring supplemental oxygen&#xD;
ICU or non-ICU hospital ward, requiring non-invasive ventilation or high-flow oxygen&#xD;
ICU, requiring intubation and mechanical ventilation&#xD;
ICU, requiring ECMO or mechanical ventilation and additional organ support&#xD;
Death</description>
        <time_frame>28 days</time_frame>
        <population>Modified intention-to-treat (mITT) population, which includes 242 patients (161 in the tocilizumab group and 81 in the placebo group) who underwent randomization and received either tocilizumab or placebo before intubation or death</population>
        <group_list>
          <group group_id="O1">
            <title>Tocilizumab</title>
            <description>Standard care plus a single dose of tocilizumab (8 mg/kg administered intravenously, not to exceed 800 mg)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Standard care plus placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Improvement on Ordinal Scale</title>
          <description>Time to first improvement from administration of the investigational agent (or placebo) of at least 2 points (or the maximum amount) on the ordinal scale. Event times for patients who died prior to reaching this endpoint are censored at 29 days.&#xD;
Ordinal Scale&#xD;
Discharged&#xD;
Non-ICU hospital ward not requiring supplemental oxygen&#xD;
Non-ICU hospital ward requiring supplemental oxygen&#xD;
ICU or non-ICU hospital ward, requiring non-invasive ventilation or high-flow oxygen&#xD;
ICU, requiring intubation and mechanical ventilation&#xD;
ICU, requiring ECMO or mechanical ventilation and additional organ support&#xD;
Death</description>
          <population>Modified intention-to-treat (mITT) population, which includes 242 patients (161 in the tocilizumab group and 81 in the placebo group) who underwent randomization and received either tocilizumab or placebo before intubation or death</population>
          <units>percentage of patients with event</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="161"/>
                <count group_id="O2" value="81"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.3" lower_limit="80.6" upper_limit="91.1"/>
                    <measurement group_id="O2" value="81.5" lower_limit="72.4" upper_limit="89.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.3" lower_limit="86.3" upper_limit="95.1"/>
                    <measurement group_id="O2" value="88.9" lower_limit="81.0" upper_limit="94.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>0-28 days. An AE is any unfavorable and unintended sign (including an abnormal laboratory finding),symptom, or disease temporally associated with the use of an investigational medicinal product (IMP) or other protocol-imposed intervention, regardless of attribution.</time_frame>
      <desc>An SAE&#xD;
death&#xD;
It is life threatening&#xD;
It requires or prolongs inpatient hospitalization.&#xD;
It results in persistent or significant disability/incapacity&#xD;
It results in a congenital anomaly/birth defect in a neonate/infant born to a mother exposed to the IMP.&#xD;
It is considered a significant medical event by the investigator based on medical judgment (e.g., may jeopardize the subject or may require medical/surgical intervention to prevent one of the outcomes listed above).</desc>
      <group_list>
        <group group_id="E1">
          <title>Tocilizumab</title>
          <description>Standard care plus a single dose of tocilizumab (8 mg/kg administered intravenously, not to exceed 800 mg)</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Standard care plus placebo</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="161"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Febrile Neutropenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Elevated Partial Thromboplastin Time</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Bleeding</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Arterial ischemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Cardiogenic Shock</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <description>to the 40's to the point of brief asystole</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Hospitalization for Syncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Continued anorexia</sub_title>
                <description>patient continues inpatient due to refusal of food and IV medications - prolong</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Elevated liver function test: Alanine aminotransferase</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Elevated liver function test: Aspartate transaminase</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="161"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hip fracture requiring hospitalization</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Stroke</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="161"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Parasthesia</sub_title>
                <description>there was noted change in neurology exam with patient now not withdrawing to pain in upper extremity</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Low output from nephrostomy tube</sub_title>
                <description>decreased urine output from his right-sided nephrostomy tube</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Patient re-hospitalized because dialysis could not be arranged any other way</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Renal injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="161"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Pulmonary Fibrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Tracheostomy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Tachypnea</sub_title>
                <description>patient experienced episode of tachypnea post bed bath(Grade 3</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <description>resulting in PEG placement</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>respiratory failure and intubation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Respiratory Acidosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hypothermia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Grade 3: Rash/allergic reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep venous thrombosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="161"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <description>after standing up - BP 79/60. IV fluid bolus given with BP back to 120s again</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="161"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>decreased white blood cell count</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="161"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="161"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>decreased hemoglobin</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>hypomagnesemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Mild edema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="161"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Paroxysmal Atrial fibrillation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear ache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="161"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Vomitting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased poly(ADP-ribosyl)ation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>worsening lower extremity wound</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>FALL WITH ABRASION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Worsening confusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <description>(including elevated creatinine, decreased GFR)</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Increased alkaline phosphatase</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>acute kidney injury with AGMA and hyperkalemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Mucus plugging</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Oropharyngeal Dysphagia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritic Rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Acute superficial thrombophlebitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>DRAI Director of Clinical Trials</name_or_title>
      <organization>Massachusetts General Hospital</organization>
      <phone>617-726-7938</phone>
      <email>JHSTONE@mgh.harvard.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

